Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

[1]  Z. Xiong,et al.  Molecular and Synaptic Bases of CDKL5 Disorder , 2018, Developmental neurobiology.

[2]  H. Leonard,et al.  Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder , 2018, Epilepsy Research.

[3]  A. Muotri,et al.  Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics , 2018, The EMBO journal.

[4]  Anup D. Patel,et al.  Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes , 2018, Epilepsy & Behavior.

[5]  H. Koga,et al.  A male case with CDKL5-associated encephalopathy manifesting transient methylmalonic acidemia. , 2018, European journal of medical genetics.

[6]  K. Holman,et al.  Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy , 2018, Seizure.

[7]  I. Scheffer,et al.  Early mortality in SCN8A-related epilepsies , 2018, Epilepsy Research.

[8]  Tim Guilliams,et al.  The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5 , 2018, Human molecular genetics.

[9]  Amanda S. Lindy,et al.  Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders , 2018, Epilepsia.

[10]  S. Bastianini,et al.  CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder , 2018, Human molecular genetics.

[11]  M. Mizuguchi,et al.  Comprehensive behavioral analysis of the Cdkl5 knockout mice revealed significant enhancement in anxiety- and fear-related behaviors and impairment in both acquisition and long-term retention of spatial reference memory , 2018, PloS one.

[12]  Amanda S. Lindy,et al.  High frequency of mosaic pathogenic variants in genes causing epilepsy-related neurodevelopmental disorders , 2017, Genetics in Medicine.

[13]  S. Cobb,et al.  CDKL5 variants , 2017, Neurology: Genetics.

[14]  T. Manabe,et al.  CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility , 2017, Neurobiology of Disease.

[15]  N. Landsberger,et al.  The neurosteroid pregnenolone reverts microtubule derangement induced by the loss of a functional CDKL5-IQGAP1 complex , 2017, Human molecular genetics.

[16]  A. Mallick,et al.  Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients. , 2017, Hippokratia.

[17]  A. Bergin,et al.  Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients , 2017, Epilepsia.

[18]  Philippe Ryvlin,et al.  Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society , 2017, Epilepsy currents.

[19]  H. Leonard,et al.  Expanding the clinical picture of the MECP2 Duplication syndrome , 2017, Clinical genetics.

[20]  T. Maehara,et al.  Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation , 2017, Brain and Development.

[21]  M. Likeman,et al.  Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial , 2017, The Lancet Neurology.

[22]  Song Han,et al.  Molecular and genetic insights into an infantile epileptic encephalopathy – CDKL5 disorder , 2017, Frontiers in Biology.

[23]  I. Scheffer,et al.  Mortality in Dravet syndrome , 2016, Epilepsy Research.

[24]  J. Christodoulou,et al.  Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder , 2016, Neurology.

[25]  M. Giustetto,et al.  Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1 , 2016, Biological Psychiatry.

[26]  J. Christodoulou,et al.  Functional abilities in children and adults with the CDKL5 disorder , 2016, American journal of medical genetics. Part A.

[27]  R. Bartesaghi,et al.  HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. , 2016, Human molecular genetics.

[28]  P. Kind,et al.  Characterisation of CDKL5 Transcript Isoforms in Human and Mouse , 2016, PloS one.

[29]  H. Leonard,et al.  Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome , 2016, Orphanet Journal of Rare Diseases.

[30]  Sucheta Joshi,et al.  Response to treatment in a prospective national infantile spasms cohort , 2016, Annals of neurology.

[31]  P. Striano,et al.  Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[32]  Eileen M. Walsh,et al.  Incidence of Dravet Syndrome in a US Population , 2015, Pediatrics.

[33]  T. Nakagawa,et al.  Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing , 2015, Brain and Development.

[34]  R. Bartesaghi,et al.  Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder , 2015, Neurobiology of Disease.

[35]  T. Hallböök,et al.  Dravet syndrome in Sweden: a population‐based study , 2015, Developmental medicine and child neurology.

[36]  M. Alders,et al.  Two Siblings With a CDKL5 Mutation , 2015, Journal of child neurology.

[37]  J. Christodoulou,et al.  There is variability in the attainment of developmental milestones in the CDKL5 disorder , 2015, Journal of Neurodevelopmental Disorders.

[38]  P. Stankiewicz,et al.  Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications , 2014, European Journal of Human Genetics.

[39]  Laurie E. Seltzer,et al.  Epilepsy and outcome in FOXG1‐related disorders , 2014, Epilepsia.

[40]  R. Zeng,et al.  Palmitoylation-dependent CDKL5–PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development , 2013, Proceedings of the National Academy of Sciences.

[41]  Meredith Wilson,et al.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.

[42]  S. Siegel,et al.  Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice , 2012, Proceedings of the National Academy of Sciences.

[43]  T. Jacques,et al.  The neuropathological consequences of CDKL5 mutation , 2012, Neuropathology and applied neurobiology.

[44]  A. Poduri,et al.  CDKL5 mutations in early onset epilepsy: Case report and review of the literature , 2012, Journal of Pediatric Epilepsy.

[45]  V. Kalscheuer,et al.  CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons , 2012, Nature Cell Biology.

[46]  H. Van Esch,et al.  Recurrent mutations in the CDKL5 gene: Genotype–phenotype relationships , 2012, American journal of medical genetics. Part A.

[47]  H. Yntema,et al.  Clinical Phenotype of 5 Females With a CDKL5 Mutation , 2012, Journal of child neurology.

[48]  H. Ikeda,et al.  CDKL5 alterations lead to early epileptic encephalopathy in both genders , 2011, Epilepsia.

[49]  P. Stankiewicz,et al.  Early-onset seizures due to mosaic exonic deletions of CDKL5 in a male and two females , 2011, Genetics in Medicine.

[50]  I. Scheffer,et al.  A distinctive seizure type in patients with CDKL5 mutations: Hypermotor-tonic-spasms sequence , 2011, Neurology.

[51]  G. Perilongo,et al.  Pathogenic Role of the X-Linked Cyclin-Dependent Kinase-Like 5 and Aristaless-Related Homeobox Genes in Epileptic Encephalopathy of Unknown Etiology With Onset in the First Year of Life , 2011, Journal of child neurology.

[52]  S. Savasta,et al.  CDKL5 gene‐related epileptic encephalopathy: electroclinical findings in the first year of life , 2011, Developmental medicine and child neurology.

[53]  P. Stankiewicz,et al.  Duplications of FOXG1 in 14q12 are associated with developmental epilepsy, mental retardation, and severe speech impairment , 2011, European Journal of Human Genetics.

[54]  Z. Xiong,et al.  CDKL5, a Protein Associated with Rett Syndrome, Regulates Neuronal Morphogenesis via Rac1 Signaling , 2010, The Journal of Neuroscience.

[55]  S. Auvin,et al.  Somatic mosaicism for a CDKL5 mutation as an epileptic encephalopathy in males , 2010, American journal of medical genetics. Part A.

[56]  S. Peters,et al.  The MECP2 duplication syndrome , 2010, American journal of medical genetics. Part A.

[57]  R. Guerrini,et al.  Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy , 2010, Epilepsia.

[58]  J. H. Cross,et al.  Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009 , 2010, Epilepsia.

[59]  M. Cilio,et al.  Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria , 2010, Brain & development (Tokyo. 1979).

[60]  F. Giuliano,et al.  Mutational spectrum of CDKL5 in early‐onset encephalopathies: a study of a large collection of French patients and review of the literature , 2009, Clinical genetics.

[61]  J. Chelly,et al.  CDKL5 MUTATIONS IN BOYS WITH SEVERE ENCEPHALOPATHY AND EARLY-ONSET INTRACTABLE EPILEPSY , 2009, Neurology.

[62]  V. Saletti,et al.  Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes , 2009, neurogenetics.

[63]  S. Sartori,et al.  A novel CDKL5 mutation in a 47,XXY boy with the early‐onset seizure variant of Rett syndrome , 2009, American journal of medical genetics. Part A.

[64]  N. Landsberger,et al.  CDKL5 Expression Is Modulated during Neuronal Development and Its Subcellular Distribution Is Tightly Regulated by the C-terminal Tail* , 2008, Journal of Biological Chemistry.

[65]  N. Boddaert,et al.  Key clinical features to identify girls with CDKL5 mutations. , 2008, Brain : a journal of neurology.

[66]  M. Fichera,et al.  CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy , 2008, Neurology.

[67]  N. Boddaert,et al.  The three stages of epilepsy in patients with CDKL5 mutations , 2008, Epilepsia.

[68]  E. Veneselli,et al.  Clinical and electroencephalographic features in patients with CDKL5 mutations: Two new Italian cases and review of the literature , 2008, Epilepsy & Behavior.

[69]  A. Renieri,et al.  Seizures and electroencephalographic findings in CDKL5 mutations: Case report and review , 2007, Brain and Development.

[70]  J. Tolmie,et al.  CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients , 2006, Journal of Medical Genetics.

[71]  Carol Bower,et al.  Rett syndrome in Australia: a review of the epidemiology. , 2006, The Journal of pediatrics.

[72]  R. Zannolli,et al.  Myoclonic encephalopathy in the CDKL5 gene mutation , 2006, Clinical Neurophysiology.

[73]  J. Osborne,et al.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial , 2005, The Lancet Neurology.

[74]  J. Gécz,et al.  Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. , 2004, American journal of human genetics.

[75]  J. Gécz,et al.  Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. , 2004, American journal of human genetics.

[76]  H. Haas,et al.  Effects of diazepines and barbiturates on hippocampal recurrent inhibition , 1977, Naunyn-Schmiedeberg's Archives of Pharmacology.

[77]  M. Majewska,et al.  Ascorbic acid protects neurons from injury induced by glutamate and NMDA. , 1990, Neuroreport.

[78]  Serge Laroche,et al.  What can the Long-Term Potentiation Procedure Tell us about the Neural Mechanisms of Learning and Memory? , 1985 .